Early detection of Alzheimer’s disease (AD) relies primarily on biomarkers in cerebrospinal fluid (CSF), such as Aβ42, Aβ42/Aβ40 ratio, p-Tau181, and total Tau (t-Tau). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.